Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fulvestrant.

M Curran1, L Wiseman

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|June 12, 2001
PubMed
Summary
This summary is machine-generated.

Fulvestrant, an estrogen receptor degrader, effectively treats advanced breast cancer in postmenopausal women. It demonstrated comparable efficacy and tolerability to anastrozole in Phase III trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bovine congenital defects recorded by veterinary practitioners.

Reproduction in domestic animals = Zuchthygiene·2023
Same author

The effectiveness of exercise interventions to increase physical activity in Cystic Fibrosis: A systematic review.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2021
Same author

The mobilisation of early mature CD56dim-CD16bright NK cells is blunted following a single bout of vigorous intensity exercise in Type 1 Diabetes.

Exercise immunology review·2020
Same author

Evaluating steady-state resting energy expenditure using indirect calorimetry in adults with overweight and obesity.

Clinical nutrition (Edinburgh, Scotland)·2019
Same author

Practice-based differences in paediatric discoid lupus erythematosus.

The British journal of dermatology·2019
Same author

A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis.

Biochemistry and biophysics reports·2018
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Fulvestrant is an estradiol analogue targeting the estrogen receptor.
  • It inhibits estrogen receptor (ER) function and promotes ER degradation.
  • Fulvestrant exhibits pure anti-estrogenic activity.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of fulvestrant compared to anastrozole.
  • To assess treatment outcomes in postmenopausal women with advanced breast cancer.

Main Methods:

  • Two Phase III clinical trials were conducted.
  • Participants received either intramuscular fulvestrant (250 mg/month) or oral anastrozole (1 mg/day).
  • Patients had advanced breast cancer and prior endocrine therapy.

Related Experiment Videos

Main Results:

  • Fulvestrant showed comparable efficacy to anastrozole in terms of time to disease progression and duration of response.
  • Median time to progression: 5.4-5.5 months (fulvestrant) vs. 3.4-5.1 months (anastrozole).
  • Median duration of response: 14.3-19.3 months (fulvestrant) vs. 10.5-14.0 months (anastrozole).

Conclusions:

  • Fulvestrant is an effective treatment option for advanced breast cancer in postmenopausal women.
  • Fulvestrant demonstrates similar tolerability to anastrozole.
  • The drug offers a valuable alternative for patients with advanced breast cancer.